新型半胱胺（2-氯乙基）亚硝基脲——胱硫醚亚硝脲的I期试验：患者内剂量递增方案
Phase I trial of cystemustine, a new cysteamine (2-chloroethyl) nitrosourea: an intrapatient escalation scheme.
作者信息
Mathé G, Misset J L, Triana B K, Godenèche D, Madelmont J C, Meyniel G
机构信息
Service des Maladies Sanguines, Immunitaires et Tumorales, Hôpital Paul-Brousse, Villejuif, France.
出版信息
Drugs Exp Clin Res. 1992;18(4):155-8.
PMID:1451646
Abstract
A trial of cystemustine, a cysteamine nitrosourea, was carried out on 34 patients with advanced malignancies at increasing dosage of the drug over a period of up to 190 days in seven or eight cycles. A partial response to treatment was obtained in three patients. A degree of haematological toxicity developed in a number of the patients.
摘要
对34例晚期恶性肿瘤患者进行了半胱胺亚硝基脲类药物丁胱亚硝脲的试验，在七至八个周期内，药物剂量逐渐增加，疗程长达190天。3例患者对治疗有部分反应。许多患者出现了一定程度的血液学毒性。
Zotero 插件